Mind boggling really - it might take years of investing in small cap biotech to fully comprehend this, and truely put things into perspective.
University of Washington (a USA top 5 cancer hospital) tweeting (see very below) suggesting this paxalisib plus radiation FDA study -
is one of their important trials. They would be conducting dozens of other trials - many in radiation.
Its not as if this trial is for some rare cancer - buts its paxalisib to make radiation work better. A potential worth therefore of many billions of dollar - the words in the tweet are not mine.... or even the company Kazia, but from this esteemed university, talking of paxalisib.
You might say with some reasonable conviction - that paxalisib is in the top 2 or 3 - most valuable cancer drugs in development.
------------------------------------------
UW RadOnc Metastasis & Developmental Therapeutics
@RadOncMTD
University of Washington Radiation Oncology Metastatic Disease and Developmental Therapeutics - new to Twitter, not great at it, good vibes only
Seattle, WAJoined June 2023
95 Following21 FollowersNot followed by anyone you’re following
Tweets
Replies
Media
Likes
UW RadOnc Metastasis & Developmental Therapeutics’s TweetsPinned
UW RadOnc Metastasis & Developmental Therapeutics
@RadOncMTD
·
Jul 22One of our important trials in the news
#PI3K#btsm@TargetedOnc@MSK_RadOnc@MiamiCancerInsttargetedonc.com
FDA Awards Fast Track Designation to Paxalisib With Radiation for Brain Metastases
An investigation of treatment with concurrent paxalisib and whole brain radiotherapy is underway in a phase 1 clinical